NASDAQ$FLNA
Filana Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the full year 2021 and provided clinical and business updates.
Cassava Sciences reported a net loss for the full year 2021 of $32.4 million, or $0.82 per share, and has $233.4 million of cash on hand. The company initiated two Phase 3 clinical studies with simufilam in the second half of 2021 and is focused on enrolling over 1,700 patients into the Phase 3 clinical program.
- Initiated two Phase 3 clinical studies with simufilam in the second half of 2021.
- Phase 3 studies are recruiting patients with mild to moderate Alzheimer’s disease.
- Over 200 patients have been screened to date for Phase 3 studies.
- Balance sheet has $233.4 million of cash.
Headline financials
Revenue & EPS history
Cassava Sciences · Revenue · Quarterly
$0
Forward guidance
Cassava Sciences expects to use $25 to $35 million in the first half of 2022, depending on patient enrollment rates and the timing of certain legal expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.3%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-5.1%
Avg return
30 days after
40%
23 / 57 earnings
Positive
+16.1%
Q4 2013
Best reaction
-12.6%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -0.5% | -16.7% | -9.0% | |
| Q3 2025 | +5.2% | -10.6% | -5.8% | |
| Q2 2025 | +5.3% | -3.9% | -7.5% | |
| Q1 2025 | -1.0% | +1.4% | -1.9% | |
| Q4 2024 | +3.3% | +17.1% | -42.1% | |
| Q3 2024 | +1.3% | -0.7% | -87.9% | |
| Q1 2024 | -2.3% | +9.0% | -7.0% | |
| Q4 2023 | -0.3% | -2.1% | -11.8% | |
| Q3 2023 | +3.3% | -8.2% | -2.8% | |
| Q2 2023 | -4.0% | -10.5% | +0.3% | |
| Q1 2023 | -4.5% | -3.9% | -2.2% | |
| Q4 2022 | +0.8% | +6.9% | -3.1% | |
| Q3 2022 | -1.2% | +6.6% | +4.6% | |
| Q2 2022 | -11.6% | +0.2% | +27.3% | |
| Q1 2022 | -5.3% | -6.3% | +37.7% | |
| Q4 2021 | -5.4% | -12.2% | -9.3% | |
| Q3 2021 | -7.6% | -22.8% | -43.8% | |
| Q2 2021 | +10.3% | +20.5% | -32.0% | |
| Q1 2021 | +12.2% | +30.0% | +55.6% | |
| Q4 2020 | -12.5% | -16.6% | -35.4% | |
| Q3 2020 | -6.5% | -21.8% | -26.4% | |
| Q2 2020 | +9.9% | +20.9% | +13.7% | |
| Q1 2020 | +0.0% | +22.8% | -67.0% | |
| Q4 2019 | +2.6% | -1.0% | +71.6% | |
| Q3 2019 | +4.7% | +3.1% | +13.4% | |
| Q2 2019 | -7.5% | -6.8% | -4.5% | |
| Q1 2019 | -2.7% | -5.3% | +1.8% | |
| Q4 2018 | -4.1% | +6.6% | -6.6% | |
| Q3 2018 | -4.1% | +0.0% | -9.0% | |
| Q2 2018 | -0.4% | +1.4% | -56.6% | |
| Q1 2018 | +12.1% | +11.5% | +26.4% | |
| Q4 2017 | -5.6% | -1.9% | +11.4% | |
| Q3 2017 | -2.6% | +3.4% | +15.0% | |
| Q2 2017 | -4.7% | +0.3% | -4.4% | |
| Q1 2017 | +2.6% | +10.4% | -19.1% | |
| Q4 2016 | +0.0% | +0.0% | +18.6% | |
| Q3 2016 | +15.4% | -1.5% | -7.7% | |
| Q2 2016 | +5.8% | +17.9% | +12.9% | |
| Q1 2016 | +3.4% | — | — | |
| Q4 2015 | +9.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -4.4% | — | — | |
| Q3 2014 | -12.6% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +16.1% | — | — | |
| Q3 2013 | -4.4% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +3.8% | — | — | |
| Q4 2012 | +3.9% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q3 2010 | +5.4% | — | — | |
| Q2 2010 | +9.1% | — | — | |
| Q1 2010 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro